Rosatom has initiated the creation of an international platform for the development of terbium-161-based radiopharmaceuticals, which can improve the effectiveness of cancer treatment and reduce the side effects of therapy. This was announced at the "World Nuclear Week" forum.
We propose to form a multinational expert group that will combine technologies for the production of the radionuclide, methods for its purification, the development of promising radiopharmaceuticals, and the exchange of clinical results
The project is designed for three years with the possibility of extension and includes regular publication of results in peer-reviewed scientific journals.
Technologies used for the production and use of lutetium-177 can be adapted for terbium-161. The additional effect of terbium-161 electrons allows for increased therapy effectiveness with minimal damage to healthy tissues.
Rosatom's scientific division manages 12 research centers, nine reactors, and more than 700 experimental facilities, producing over ten radiopharmaceuticals. A large radiopharmaceutical plant is under construction in Obninsk, with launch scheduled for next year.